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Introduction
Brachial blood pressure (BP) increases with exercise and 
an exaggerated rise in BP during exercise has been shown 
to be an independent predictor of myocardial infarction, 
left ventricular hypertrophy, stroke and cardiovascular 
death.1–4 It is, however, well recognized that brachial BP 
can be an imperfect surrogate for the corresponding central 
aortic pressure at the aortic root, due to variation in the 
degree of aortic–brachial pressure amplification. To date, 
the effect of exercise on central aortic pressure has received 
little attention, in part due to the complexity of undertak-
ing such measurements during active exercise. Early inva-
sive studies with direct measurement of aortic pressure 
demonstrated an exaggeration of pressure amplification 
from the aortic root to the periphery with vigorous exer-
cise, such that the exercise-induced rise in peripheral 
pressure was found to exceed the rise in central pressure.5,6 
More recently these differential effects of exercise on 
peripheral and central pressure have been confirmed using 
non-invasive methods based on peripheral pulse wave 
analysis, suggesting that the magnitude of pressure 
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amplification may depend upon the type and extent of 
exercise undertaken, as well as age and other factors.7–11
Remarkably, to date no previous study has reported the 
effects of BP-lowering treatment on the response of central 
pressure to exercise. We recently reported in this journal data 
from a study evaluating the effects of two different strategies 
for therapeutic inhibition of the renin–angiotensin system 
(RAS) on brachial BP during exercise. This study compared 
the direct renin-inhibitor aliskiren with the angiotensin recep-
tor blocker valsartan and showed that both treatments simi-
larly attenuated an exercise-induced rise in brachial pressure.12 
In that study, central aortic pressure was also recorded non-
invasively via pulse wave analysis, using tonometry (BPro™, 
HealthSTATS International, Singapore) and mathematical 
computation of the radial pressure wave.13 These data are pre-
sented in the current report and describes for the first time the 
effects of BP-lowering therapy on the relationship between 
central aortic and brachial pressures during exercise.
Patients and methods
The results presented in this paper derive from both pre-
specified and exploratory analysis of data from patients 
recruited into a multicentre randomized controlled trial 
(RCT) evaluating the effects of RAS blockade on bra-
chial and central aortic pressures (ClinicalTrials.gov 
NCT00819767) and EUDRA CT (2008-005500-10).12
Patients
Men and women aged ≥ 50 years with stage 1–2 hyperten-
sion (mean sitting systolic BP (msSBP) ≥ 140 mmHg and 
< 180 mmHg, and mean sitting diastolic BP (msDBP) < 
110 mmHg, measured at rest) were eligible for inclusion. 
In addition, patients had to be anticipated to be able to 
reach peak exercise capacity (85% of their predicted maxi-
mum heart rate) during a treadmill exercise test conducted 
according to the standard Bruce protocol.
The main exclusion criteria included: secondary hyper-
tension, therapy with more than two antihypertensive 
drugs, a history of severe cardiovascular or cerebrovascu-
lar disease, known Keith–Wagener grade III or IV hyper-
tensive retinopathy, and type I diabetes. Pregnant or 
nursing women were also excluded. All patients provided 
written informed consent before participating in any study 
procedures and all study centres received approval from 
the relevant local and central ethical review boards.
Study design
The study design has been reported previously12 and is 
outlined below.
The study from which data were analysed was a rand-
omized, double blind, parallel-group study. After a two-week 
washout and a one- to two-week placebo run-in period, 
eligible patients were randomized to once-daily aliskiren 150 
mg or valsartan 160 mg for one week, with forced titration to 
double the initial dose for a further seven weeks (Figure 1). 
Three treadmill exercise tests were conducted using the 
standard Bruce protocol at: (i) baseline (immediately prior to 
randomization), (ii) at the end of the active treatment period 
(week 8) and (iii) 48 hours after treatment withdrawal, to 
evaluate the persistence of the treatment effect two days after 
treatment withdrawal (missed dose, week 8 + 2 days).
Exercise tests were conducted according to American 
College of Cardiology/American Heart Association (ACC/
AHA)14 and European Society of Cardiology (ESC) guide-
lines for exercise testing15 and patients were closely moni-
tored before, during and after the tests. Electrocardiogram 
(ECG) monitoring was continuously performed during the 
test to ensure patient safety and tests could be stopped if any 
of several ECG criteria were met (such as severe ST-segment 
depression; ST-segment elevation; frequent ventricular 
extra-systoles; onset of ventricular tachycardia).
Study assessments
The main objective of this analysis was to assess the exer-
cise-induced changes in central aortic systolic pressure 
(CASP) relative to the corresponding changes in standing 
brachial BP after eight weeks of aliskiren or valsartan ther-
apy and following treatment withdrawal. Our primary 
focus was on CASP because the measurement of pulse 
pressure (brachial and central) is dependent upon accu-
rately determining true diastolic pressure, which we found 
to be less reliable with manual sphygmomanometry during 
exercise. The primary endpoint for this analysis was the 
change in systolic pressure amplification from rest to peak 
exercise, comparing baseline with end of treatment (eight 
weeks). Changes in other central haemodynamic variables 
during exercise were also investigated. In order to stand-
ardize exercise effort according to the Bruce protocol, 
incremental treadmill exercise was maintained by each 
participant until 85% predicted maximal heart rate (HR) 
had been achieved (100% of predicted HR: female 200 – 
age; male 220 – age).
For the primary analysis, due to the limited size of the 
study, baseline and treatment data for the study population 
were pooled to assess the physiological effects of exercise 
on brachial and central pressure parameters. This was a 
reasonable approach as we had shown that both valsartan 
and aliskiren had had similar effects on brachial pressure 
at rest and during exercise.12 Brachial BP and CASP were 
measured whilst standing at rest, at peak exercise and dur-
ing the recovery phase, prior to administering study medi-
cation. Other central haemodynamic variables, including 
systolic pressure amplification ratio (calculated as bra-
chial/central BP), were also recorded.
Standing BP provided the baseline (at rest) value for the 
exercise test, and was the mean of three measurements 
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taken at 1–2-min intervals prior to the test. Standing BP 
was also measured during exercise at the end of each 3-min 
period, immediately after reaching peak exercise capacity 
and during the recovery period (10, 20 and 30 min after 
peak exercise; Figure 1 and Supplementary Digital Content 
Figure 1 online). A mercury sphygmomanometer was used 
for brachial BP measurement due to the recognized unreli-
ability of automated BP measurement during exercise. 
Systolic BP was defined according to the onset of Korotkoff 
phase I sounds, whilst diastolic pressure was defined using 
Korotkoff phase IV sounds.
Measurement of central aortic pressure. Central aortic 
pressures were measured using the BPro™ device 
(HealthSTATS International, Singapore) during each 
exercise test at rest, at peak exercise and during recovery 
(at 10, 20 and 30 min after peak exercise). The device, 
designed like a wrist watch, uses applanation tonometry to 
capture radial artery waveforms, which are calibrated 
to brachial BP and processed using a validated algorithm 
to derive central aortic pressures.13,16 The device was 
worn clamped to the wrist using a ‘square lock’ restraint, 
which allowed reliable and consistent recording of high-
fidelity radial artery waveforms during exercise testing. 
At rest, waveforms were captured immediately following 
the final of three brachial blood pressure measurements 
(within 15 s) and calibrated to the averaged brachial 
blood pressure. At peak exercise and during the recovery 
period, waveforms were captured immediately following 
the first brachial blood pressure measurement with the 
participant temporarily stationary and with their wrist 
held still at heart level. Captured waveforms were back-
calibrated to the appropriate brachial blood pressure 
value. For all measurements using the BPro™ device, 
arterial pressure waveforms were sampled in 10-s blocks 
over the course of 20–30 s and the first stable waveform 
block used for data analysis. In selecting the first stable 
waveform block, waveforms were visually inspected for 
anomalies by an experienced operator and quality control 
criteria applied to ensure adequate pulse height (100 mV) 
and pulse length variability (<20%).
Statistical analyses
The study population was defined as those participants com-
pleting central and brachial blood pressure measurements 
both at rest and at peak exercise. Normally distributed vari-
ables are presented as mean ± SD, non-normally distributed 
data are presented as median ± interquartile range. 
Comparison between continuous variables used paired 
Student’s t-test or repeated measures analysis of variance. In 
all tests a two-tailed p-value of ≤0.05 was considered statisti-
cally significant. Database management and statistical analy-
sis were performed using IBM SPSS for Windows version 
20 (IBM corporation, Armonk, NY, USA).
Results
We have previously reported in this journal the influence 
of BP lowering during exercise testing on brachial blood 
Figure 1. Overall study design. All doses were administered once daily.
aNumber of randomized patients.
bExercise tests were performed according to the standard Bruce protocol to peak exercise capacity (85% of predicted maximum heart rate).
BP: blood pressure; CASP: central aortic systolic pressure
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pressure in 68 participants.12 Of these, 32 participants (16 
aliskiren, 16 valsartan) completed central pressure record-
ings both at rest and at peak exercise across the eight week 
treatment period. The present report describes the influ-
ence of BP lowering on brachial and central pressure dur-
ing exercise testing in these 32 participants.
Patient disposition and baseline characteristics
More than two-thirds of patients in the study were male 
(68.8%) and almost all were Caucasian (96.9%). Mean age 
was 59.2 years, and 34.4% of patients were obese (body 
mass index (BMI) ≥ 30 kg/m2) with a mean BMI of 28.8 
kg/m2 (Table 1). The baseline characteristics of the study 
population were similar to those previously reported for 
the entire patient population12 (n=68).
Effects of exercise on CASP and brachial BP at 
baseline in the pooled population
At baseline, as expected, standing CASP was lower than 
standing brachial SBP at rest (137.0±10.3 vs. 150.9±10.9 
mmHg) in the pooled patient population (n=32). CASP 
increased from rest to peak exercise by a mean of 30±25.5 
mmHg, and then fell to below the resting level during the 
recovery period (Figure 2). The changes in standing bra-
chial SBP showed a similar profile during exercise (Figure 
2), although the mean increase from rest to peak exercise 
(50.6±28.4 mmHg) was much greater than that for CASP 
(p<0.01). Systolic pressure amplification, that is, the ratio 
between CASP and brachial SBP, together with the differ-
ence between brachial and central pressures, showed a 
marked elevation with peak exercise before declining to 
resting values during recovery (Figure 3).
Effects of BP lowering at rest and during 
exercise in the pooled population
Eight weeks’ BP-lowering treatment was associated with 
reductions in both brachial SBP and CASP from baseline at 
rest (Figure 2). Eight weeks’ treatment was also associated 
with reductions in brachial SBP and CASP at peak exercise. 
The extent of the treatment-induced reductions at rest and 
peak exercise did not differ when compared (reduction in 
brachial SBP: rest –15.9±13.0 mmHg, peak exercise 
–12.7±25.9; difference 3.2±26.5 mmHg, p=0.5; reduction 
in CASP: rest –16.1±13.5 mmHg, peak exercise –8.9±23.3 
mmHg; difference 7.1±24.6 mmHg, p=0.11). Similarly, the 
extent of the increase in brachial SBP and CASP from rest 
to peak exercise did not differ between baseline and after 
eight weeks’ treatment (brachial SBP change (rest–peak 
exercise): baseline 50.6±28.4 mmHg; eight weeks’ treat-
ment 53.8±21.7 mmHg, p=0.5; CASP change (rest–peak 
exercise): baseline 30±25.5 mmHg; eight weeks’ treatment 
37.1±19.2 mmHg, p=0.11). Whilst statistical analysis 
revealed no difference between the effects of treatment at 
rest and peak exercise, a trend towards a lesser reduction in 
CASP, however, was apparent at peak exercise relative to 
rest. Similarly, a trend toward a greater increase in CASP 
Table 1. Patient demographics and baseline characteristics.
All patients Aliskiren Valsartan
 (n = 32) (n = 16) (n = 16)
Age, years 59.2 ± 8.2 58.9 ± 7.9 59.5 ± 8.7
 ≥ 65 years, n (%) 5 (15.6) 3 (18.8) 2 (12.5)
Gender, n (%)
 Male 22 (68.8) 12 (75.0) 10 (62.5)
 Female 10 (31.2) 4 (25.0) 6 (37.5)
Race, n (%)
 Caucasian 31 (96.9) 15 (93.8) 16 (100)
 Asian 1 (3.1) 1 (6.2) 0 (0)
Diabetes, n (%) 3 (9.3) 1 (6.3) 2 (12.5)
BMI, kg/m2 28.8 ± 2.8 29.1 ± 2.4 28.6 ± 3.2
Obesitya, n (%) 11 (34.4) 5 (31.3) 6 (37.5)
Mean BP at rest, mmHg
 Standing SBP 149.8±10.1 149.4±10.6 150.1±10.0
 Standing DBP 92.2±7.8 91.4±8.3 90.8±7.1
 Sitting SBP 149.5±8.7 149.1±8.5 150.0±9.1
 Sitting DBP 90.4±7.1 91.4±8.3 89.3±5.7
Data are for the randomized set. Values are presented as mean ± 
standard deviation unless otherwise stated.
aBMI ≥ 30 kg/m2.
BMI: body mass index; BP: blood pressure; DBP: diastolic blood pres-
sure; SBP: systolic blood pressure
Figure 2. Influence of blood pressure-lowering treatment 
on brachial and central blood pressure during exercise in the 
pooled population. Data were analysed at baseline, after eight 
weeks of treatment and 48 hours after a missed dose. Data 
show mean ± SEM.
*p<0.05, **p<0.01 versus respective baseline value.
BrSBP: brachial systolic blood pressure; CASP: central aortic systolic 
pressure
 at University College London on May 5, 2015jra.sagepub.comDownloaded from 
Lacy et al. 5
with achievement of peak exercise was seen following 
eight weeks’ treatment relative to baseline. Importantly, as 
reported at baseline, the rise in brachial SBP exceeded the 
rise in CASP following eight weeks’ treatment.
Systolic pressure amplification and the difference 
between brachial and central pressure both showed an 
increase from rest to peak exercise (Figure 3). The extent 
of these increases with exercise did not differ between 
baseline and after eight weeks’ treatment (increase in sys-
tolic amplification (rest to peak exercise) at baseline 
0.11±0.09; increase in systolic amplification (rest to peak 
exercise) after eight weeks’ treatment 0.08±0.1; difference 
0.03±0.1, p=0.08; increase in brachial minus central pres-
sure (rest to peak exercise) at baseline 20.6±13 mmHg; 
increase in brachial minus central pressure (rest to peak 
exercise) after eight weeks’ treatment 16.7±13.2 mmHg; 
difference 3.9±14.8 mmHg, p=0.15). However, consistent 
with the effects of treatment on CASP relative to brachial 
SBP, trends towards lesser increases in systolic amplifica-
tion and the difference between brachial and central pres-
sure were seen with exercise, following eight weeks’ 
treatment (Supplementary Digital Content Figure 2).
These data indicate that whilst eight weeks’ treatment 
reduced brachial and central BP both at rest and at peak 
exercise, the pattern of change in these parameters with 
exercise remained essentially unaltered. This was seen in 
spite of some residual variability in the effects of treatment 
on central pressure at peak exercise.
Effects of a missed medication dose on BP 
lowering at rest and during exercise in the 
pooled population
Forty-eight hours after a missed medication dose, brachial 
and central pressures remained unaltered both at rest and at 
peak exercise relative to values seen after eight weeks’ 
treatment (Figure 2). Similarly, the increase with exercise 
in systolic pressure amplification and the difference 
between brachial and central pressure remained unchanged 
relative to that seen at eight weeks or baseline following a 
missed medication dose (Figure 3).
Analysis of data by BP-lowering treatment type
Whilst this study was not powered to demonstrate differ-
ences in exercise haemodynamics between treatments, the 
changes in brachial and central pressure during exercise 
were broadly similar when the two different treatments 
(aliskiren versus valsartan) were compared (Figure 4).
Discussion
To our knowledge, this is the first report of the influence of 
BP lowering on exercise-induced change in brachial and 
central blood pressure in people with hypertension. The 
main findings are that the rise in central pressure from rest 
to peak exercise was markedly lower than the correspond-
ing rise in brachial pressure, consistent with increased 
aortic–brachial systolic pressure amplification during exer-
cise. Blood pressure lowering treatment for eight weeks 
reduced both brachial and central pressures at rest and dur-
ing exercise. However, the reductions in aortic and brachial 
pressures following treatment were proportionate to the 
pre-treatment relationship between aortic and brachial 
pressures, at all time points. These findings demonstrate for 
the first time that BP-lowering treatment, at least with the 
drugs tested here, does not exert a major influence on the 
relationship between aortic and brachial pressure at rest and 
during exercise, other than through proportionate lowering 
of both pressures. Consistent with the latter, the increased 
systolic pressure amplification associated with peak exer-
cise was not significantly modulated by BP-lowering treat-
ment, nor was there any significant treatment-induced 
Figure 3. Influence of BP-lowering treatment on systolic 
pressure amplification and the difference between brachial and 
central pressure during exercise in the pooled population. Data 
show mean ± SEM.
**p<0.01 versus value at rest.
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change in the difference between aortic and brachial pres-
sure at corresponding time points. If anything, there was a 
trend toward a lesser reduction in central relative to bra-
chial pressure at peak exercise, together with a trend to a 
smaller exercise-induced increase in systolic amplification 
following eight weeks’ treatment, which did not achieve 
statistical significance. Finally, the beneficial influence of 
treatment on brachial and central pressure during exercise 
was not diminished 48 h after medication withdrawal, sim-
ulating a missed medication dose.
The exaggeration of systolic and pulse pressure ampli-
fication with exercise has been demonstrated in previous 
studies using both direct5,6 and indirect7–11 measurement of 
aortic pressure waveforms, together with contemporane-
ous measurement of peripheral BP. This indicates that the 
true pressure excursion (i.e. central pressure) during exer-
cise is much less dramatic than the typical rise in brachial 
pressure. This may be a direct consequence of functional 
changes in the systemic circulation in response to the 
demands of the working musculature for increased perfu-
sion, but may also serve to protect the major organs against 
excessive pressure elevations during the exercise period.
The mechanism for the increase in systolic pressure 
amplification during exercise has not been fully eluci-
dated. Dynamic exercise is associated with increases in 
cardiac output, heart rate and sympathetic mediated vaso-
constriction and venoconstriction. In addition to the conse-
quent elevation in systemic BP in response to exercise, 
stimuli within the exercising musculature mediate local-
ized vasodilatation in response to the increased metabolic 
activity to maintain adequate muscle perfusion. Thus 
assessment of central BP together with peripheral blood 
pressure as measured over a non-working musculature, for 
example, over the brachial artery in the case of treadmill 
exercise, demonstrates enhanced pressure amplification 
relative to the resting state.5–11 By contrast, the degree of 
central to peripheral amplification has been reported to be 
attenuated when peripheral pressure is measured over the 
working muscle5 as a consequence of local vasodilatation 
in the working limb.17,18 Similarly, the exercise-induced 
enhancement in central to peripheral amplification meas-
ured over the non-working muscle has been reported to be 
attenuated following initiation of local vasodilator stimuli 
such as induction of reactive hyperaemia6 or application of 
heat locally.19 These observations indicate that the 
increased pressure amplification induced by exercise may 
be modulated by local conditions and may involve changes 
to pressure wave reflections in the face of an unchanged or 
diminished aortic impedance. Alternatively the enhanced 
amplification may result as a consequence of increased 
blood flow into a vasoconstricted vasculature and may also 
result in part from enhanced sensitivity of central BP to 
increasing HR.20
Our observation that the enhancement in pressure ampli-
fication with exercise remained relatively unchanged 
despite BP lowering is intriguing. It suggests either that in 
spite of effective BP lowering, RAS blockade does not 
directly affect the physiological performance of the arterial 
system during exercise, or that global changes to the physi-
cal characteristics of the arterial system do not modulate 
the pressure amplification response to exercise. The latter is 
consistent with other studies investigating the influence of 
factors such as diabetes or ageing on pressure amplifica-
tion. Thus, whilst type 2 diabetes has been associated with 
exaggerated brachial and central BP responses to exercise 
relative to age- and gender-matched people without diabe-
tes, no difference in systolic or pulse pressure amplification 
between groups was reported either at baseline or following 
exercise.21 In a study comparing the effects of exercise on 
brachial and central pressure in groups of young and older 
men, Casey and colleagues11 reported that whilst ageing 
was associated with changes to brachial and central pres-
sure at both rest and peak exercise, there was little differ-
ence in the magnitude of the pressure amplification change 
Figure 4. Influence of treatment type on brachial SBP and 
CASP during exercise. Data are shown at baseline, after eight 
weeks of treatment and 48 hours after a missed dose. Upper 
panel: aliskiren; lower panel: valsartan. Data show mean ± SEM.
*p<0.05, **p<0.01 versus respective baseline value.
BrSBP: brachial systolic blood pressure; CASP: central aortic systolic 
pressure
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to exercise in relation to age. Similar data were reported by 
Sharman and colleagues10 with regard to the influence of 
age on the exercise-mediated change from baseline values 
in pressure amplification. However, these workers also 
reported a reduction in the extent of exercise-induced ampli-
fication in the presence of hypercholesterolaemia. This was 
interpreted to indicate that exercise-induced elevations in 
pressure amplification were attenuated by enhanced periph-
eral pressure wave reflections resulting from impaired 
endothelial function with hypercholesterolaemia.
Our findings would not necessarily support a major role 
for wave reflection. Treatment-induced reduction in wave 
reflections might have been expected to minimize the 
exercise-induced increase in central relative to brachial 
pressure, thereby enhancing the amplification response. 
Instead, we found a trend towards an attenuated exercise-
induced increase in amplification following treatment, 
which is difficult to reconcile with the concept of benefi-
cial effects of treatment on wave reflections.
Our suggestion that wave reflections are unlikely to 
play a major role in modulating exercise-mediated pres-
sure amplification is supported by recent work using wave 
separation analysis during moderate exercise22,23 which 
indicates that changes in pressure amplification with exer-
cise are independent of changes to arterial pressure wave 
reflections. Similarly, other studies investigating the influ-
ence of short-term infusion with noradrenaline or inhibi-
tors of nitric oxide synthase (LNMMA) on the change in 
pressure amplification during exercise8 report no change 
to the exercise-induced increase in pressure amplification 
with drug infusion. These data are also consistent with the 
notion that exercise-induced changes to pressure amplifi-
cation are independent of global change in arterial physical 
characteristics.
A key issue for the interpretation of exercise studies 
using non-invasive measurements of central pressure is 
whether exercise itself has any influence on the method for 
deriving central pressure. Previous studies have produced 
equivocal findings. Sharman and colleagues, using a com-
mercially available generalized transfer function for deriv-
ing central pressure, reported no influence of exercise on 
non-invasively-derived central pressure in a small group of 
patients referred for diagnostic cardiac catheterization.7 
Similarly Holland and colleagues24 reported non-inva-
sively-derived central pressure to be a reproducible and 
reliable technique during haemodynamic perturbations 
induced by exercise. However, using a radial to carotid 
transfer function, Payne and colleagues reported that exer-
cise was associated with an underestimation of transfer 
function-derived carotid pressure compared with directly 
measured carotid pressure, in a group of healthy men 
undergoing moderate exercise.25 Other workers using a 
digital to aortic transfer function generated in cardiac 
patients reported that exercise modulates the characteristics 
of the transfer function such that derivation of aortic 
pressure became unreliable, especially at higher heart 
rates.26 Importantly, however, the extent of any possible 
underestimation in central systolic pressure defined in these 
studies was small, that is, no more than 5mmHg, when 
compared with the rise in central pressure with exercise 
(circa 30mmHg in our study) and is comparable to the vari-
ability typically seen in comparisons between invasively-
measured and non-invasively-derived central pressure.
By contrast, studies using direct invasive measurement 
of aortic pressure suggest little influence of exercise on 
aortic waveform shape,27 or on the impedance spectrum,22 
indicating that underestimation of central pressure in non-
invasive studies may be specific to use of a generalized 
transfer function derived at rest. The present study used 
low-pass filtering via a N-point moving average to derive 
central pressure non-invasively rather than using a gener-
alized transfer function. Whilst exercise was associated 
with modulation to the shape of the radial pressure wave, 
whether exercise potentially modulates the degree of fil-
tering required accurately to derive central pressure is 
unknown.
The persistence of BP-lowering effects following a 
missed dose of BP-lowering medication, which mimics 
lack of compliance to treatment, is another important treat-
ment consideration.28 For sportsmen and very active indi-
viduals, the effects of a missed dose on the changes in BP 
during exercise are of particular clinical importance, given 
the relationship between exercise-induced rises in SBP and 
adverse clinical outcomes.1–4 The current study suggests 
that the beneficial effects of BP lowering with valsartan or 
aliskiren were maintained following a missed dose, even 
during the stress induced by vigorous exercise. This find-
ing is consistent with data from the ASSERTIVE study, 
which compared the effect of aliskiren and telmisartan on 
BP after a one-week treatment withdrawal.29,30
The present study has a number of limitations, which 
should be addressed. This was a small study with an 
exploratory objective to investigate the influence of 
RAS-blocking treatment on the exercise-induced rise in 
central pressure. As such it was not powered to demon-
strate differences in central pressures or related haemo-
dynamic parameters between the two different treatments 
used in the study. Similarly, the study was not powered 
to investigate the response of central pressure elevation 
to exercise by age, gender or height. Nevertheless, our 
study was well powered to show changes in both bra-
chial and central blood pressure and amplification in 
response to exercise and the data are consistent with pre-
viously published reports. However, this is the first study 
to report the effects of BP-lowering treatment on exer-
cise-induced pressure amplification change. As such it 
was not possible, a priori, to calculate the necessary 
sample size required should a change in the amplifica-
tion response to exercise become apparent – especially 
one that trended in the opposite direction to what many 
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might have predicted. An indicative, retrospective power 
calculation indicates that the study would have required 
77 participants to demonstrate a significant decrease in 
systolic pressure amplification and a sample size of 115 to 
show a significant change for the difference between bra-
chial and central pressure with exercise between baseline 
and end of treatment. This information will be useful for 
calculating statistical power for future studies of this 
kind. We focused on systolic pressure amplification 
rather than pulse pressure. Although diastolic pressures 
were measured at rest and during exercise, the investiga-
tors noted that the measurement of DBP by auscultation 
(Korotkoff phase IV) during exercise was problematic 
due to noise and movement, and less reliable than sys-
tolic pressure recordings. Moreover, other workers have 
reported rhythmic variations in pulse pressure associated 
with exercise, particularly upright dynamic exercise.31,32 
We therefore elected to focus our data analysis on systolic 
pressure. Undertaking detailed physiological studies dur-
ing exercise is complex. Despite the small numbers, our 
findings clearly demonstrate that BP lowering does not 
enhance exercise-mediated pressure amplification. If any-
thing there was a trend to the opposite direction, that is, 
towards an attenuation in exercise-mediated amplification. 
Importantly, these data were recorded within the rigorous 
context of a randomized clinical trial of BP lowering.
In conclusion, this study reports for the first time that 
BP lowering treatment, at least with the RAS-blocking 
drugs tested here, did not directly influence the relation-
ship between aortic and brachial pressure at rest and dur-
ing exercise, other than through proportionate lowering of 
both pressures. Further work is needed to better understand 
the mechanisms underpinning aortic–brachial pressure 
amplification during exercise.
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